|
1
|
Chen Y, Yang Y, Liu L, Wang S, Song H and
Liu X: Tumor suppressor in lung cancer-1 is a prognostic predictor
for the recurrence and progression of non-muscle-invasive bladder
cancer. Urol Int. 96:142–147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jayaratna IS, Navai N and Dinney CP: Risk
based neoadjuvant chemotherapy in muscle invasive bladder cancer.
Transl Androl Urol. 4:273–282. 2015.PubMed/NCBI
|
|
3
|
Izumi K, Ito Y, Miyamoto H, Miyoshi Y, Ota
J, Moriyama M, Murai T, Hayashi H, Inayama Y, Ohashi K, et al:
Expression of androgen receptor in non-muscle-invasive bladder
cancer predicts the preventive effect of androgen deprivation
therapy on tumor recurrence. Oncotarget. 7:14153–14160. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Byun SJ, Kim JH, Oh YK and Kim BH:
Concurrent chemoradiotherapy improves survival outcome in
muscle-invasive bladder cancer. Radiat Oncol J. 33:294–300. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun L, Lu J, Niu Z, Ding K, Bi D, Liu S,
Li J, Wu F, Zhang H, Zhao Z and Ding S: A Potent chemotherapeutic
strategy with Eg5 inhibitor against gemcitabine resistant bladder
cancer. PLoS One. 10:e01444842015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vasquez JL, Gehl J and Hermann GG:
Electroporation enhances mitomycin C cytotoxicity on T24 bladder
cancer cell line: A potential improvement of intravesical
chemotherapy in bladder cancer. Bioelectrochemistry. 88:127–133.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gederaas OA, Søgaard CD, Viset T, Bachke
S, Bruheim P, Arum CJ and Otterlei M: Increased anticancer efficacy
of intravesical mitomycin c therapy when combined with a PCNA
targeting peptide. Transl Oncol. 7:812–823. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang H, Qi F, Cao Y, Zu X, Chen M, Li Z
and Qi L: 5-Aza-2′-deoxycytidine enhances maspin expression and
inhibits proliferation, migration, and invasion of the bladder
cancer T24 cell line. Cancer Biother Radiopharm. 28:343–350. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Higgins CF: ABC transporters: From
microorganisms to man. Annu Rev Cell Biol. 8:67–113. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sedláková I, Laco J, Caltová K, Červinka
M, Tošner J, Řezáč A and Špaček J: Clinical significance of the
resistance proteins LRP, Pgp, MRP1, MRP3 and MRP5 in epithelial
ovarian cancer. Int J Gynecol Cancer. 25:236–243. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kovalev AA, Tsvetaeva DA and Grudinskaja
TV: Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the
development of primary and acquired multiple drug resistance in
patients with early and metastatic breast cancer. Exp Oncol.
35:287–290. 2013.PubMed/NCBI
|
|
12
|
Roundhill E and Burchill S: Membrane
expression of MRP-1, but not MRP-1 splicing or Pgp expression,
predicts survival in patients with ESFT. Br J Cancer. 109:195–206.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang X, Shen J, Gao Y, Feng Y, Guan Y,
Zhang Z, Mankin H, Hornicek FJ and Duan Z: Nsc23925 prevents the
development of paclitaxel resistance by inhibiting the introduction
of P-glycoprotein and enhancing apoptosis. Int J Cancer.
137:2029–2039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Katagiri H, Nakayama K, Razia S, Nakamura
K, Sato E, Ishibashi T, Ishikawa M, Iida K, Ishikawa N, Otsuki Y,
et al: Loss of autophagy-related protein Beclin 1 may define poor
prognosis in ovarian clear cell carcinomas. Int J Oncol.
47:2037–2044. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartsch G, Jennewein L, Harter PN,
Antonietti P, Blaheta RA, Kvasnicka HM, Kögel D, Haferkamp A,
Mittelbronn M and Mani J: Autophagy-associated proteins BAG3 and
p62 in testicular cancer. Oncol Rep. 35:1629–1635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ge J and Chen Z, Huang J, Chen J, Yuan W,
Deng Z and Chen Z: Upregulation of autophagy-related gene-5 (ATG-5)
is associated with chemoresistance in human gastric cancer. PLoS
One. 9:e1102932014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Levine B: Cell biology: Autophagy and
cancer. Nature. 446:745–747. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang Z, Zhao T, Liu H and Zhang L:
Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin
and autophagy. Sci Rep. 6:193832016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang SJ, Ou-Yang F, Tu HP, Lin CH, Huang
SH, Kostoro J, Hou MF, Chai CY and Kwan AL: Decreased expression of
autophagy protein LC3 and stemness
(CD44+/CD24−/low) indicate poor prognosis in
triple-negative breast cancer. Hum Pathol. 48:48–55. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masuda GO, Yashiro M, Kitayama K, Miki Y,
Kasashima H, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T,
Sakurai K, et al: Clinicopathological correlations of
autophagy-related proteins LC3, Beclin 1 and p62 in gastric cancer.
Anticancer Res. 36:129–136. 2016.PubMed/NCBI
|
|
21
|
Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y
and Fan Y: Upregulated SMYD3 promotes bladder cancer progression by
targeting BCLAF1 and activating autophagy. Tumour Biol.
37:7371–7381. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu T, Wang MC, Jing L, Liu ZY, Guo H, Liu
Y, Bai YY, Cheng YZ, Nan KJ and Liang X: Autophagy facilitates lung
adenocarcinoma resistance to cisplatin treatment by activation of
AMPK/mTOR signaling pathway. Drug Des Devel Ther. 9:6421–6431.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang MC, Wang HC, Hou YC, Tung HL, Chiu TJ
and Shan YS: Blockade of autophagy reduces pancreatic cancer stem
cell activity and potentiates the tumoricidal effect of
gemcitabine. Mol Cancer. 14:1792015. View Article : Google Scholar : PubMed/NCBI
|
